Nephrocare Health Services Q1 FY27: Profit turns positive

Key update investors are tracking

Nephrocare Health Services Ltd, which operates dialysis centres under the NephroPlus brand, is in focus ahead of its scheduled board meeting on 11 August 2026. The company has informed BSE that the board will consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026.

In the lead-up to the meeting, the latest quarter snapshot circulating in market data shows a shift into profitability for the June 2026 quarter. The same data also indicates a sharp rise in sales compared with the year-ago period.

June 2026 quarter: profit swings from loss to profit

For the quarter ended June 2026, Nephro Care India is reported to have posted a net profit of ₹1.61 crore. This compares with a net loss of ₹0.65 crore in the quarter ended June 2025 (as presented in the provided data).

The improvement is notable because it reflects a move from loss to profit within the comparable quarter window. However, investors typically await the company’s exchange filing for the final audited or unaudited numbers and segment-level commentary.

Sales rise 68.44% in the June 2026 quarter

Sales for the quarter ended June 2026 are reported at ₹29.19 crore, up 68.44% from ₹17.33 crore in the quarter ended June 2025. The jump in sales, alongside the profitability turnaround, is likely to draw attention as investors evaluate the company’s near-term operating momentum.

The numbers in the provided text are presented as quarter-ended figures, and market participants generally cross-check such figures with NSE/BSE filings once results are formally released.

Board meeting scheduled on 11 August 2026

Nephrocare Health Services disclosed a board meeting intimation stating that the meeting of the board of directors is scheduled on 11/08/2026. The stated agenda includes considering and approving the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026.

Separately, the dataset also references an “Announcement under Regulation 30 (LODR) - Analyst / Investor Meet - Intimation.” While no additional details are provided here, such disclosures typically alert markets to planned investor communications.

Share price levels cited across dates

Multiple price points are referenced in the provided material:

• As of 2 Aug 2026, Nephrocare Health Services share price is stated as ₹681.6.
• As on 31/7/2026, it is stated as ₹681.65 on NSE and ₹681.75 on BSE.
• The dataset also cites “CMP ₹672” alongside market-cap and target estimates.
• Another data point states the share price as ₹697.70 as on 10 Aug 2026 at 03:55 PM.

These datapoints reflect different timestamps and sources. Investors typically rely on exchange prices and corporate filings as the primary reference during results season.

FY26 performance snapshot from the provided data

The material also includes a broader annual performance snapshot for FY 2025-26:

• FY26 revenue: ₹998.8 crore (up 32.2% year-on-year)
• Q4 revenue: ₹265.6 crore (up 21.2% year-on-year)
• Adjusted EBITDA (ex-ESOP and Saudi expenses): ₹238.1 crore (up 37.6% year-on-year), with margin at 23.8% (from 22.8%)
• Adjusted PAT: ₹128.3 crore (up 74.6% year-on-year), PAT margin at 12.8% (from 9.7%)
• Q4 adjusted PAT: ₹35.1 crore (up 27.4% year-on-year)
• Q4 EBITDA margin was impacted by a one-time ₹10 crore ECL provision
• Revenue per treatment (RPT): ₹2,598 (up 13.3%)
• Operating cash flow: ₹233 crore; free cash flow: ₹68 crore; cash balance: ₹500 crore

These figures provide useful context on scale, margins, and cash flows when comparing the company’s annual trajectory with the smaller quarter snapshot referenced for June 2026.

Market metrics and expectations mentioned

The dataset provides a basic market snapshot used by some market trackers:

• CMP: ₹672
• Market cap: ₹6,745 crore
• P/E: Not meaningful
• 12-month target (Uniresearch estimate): ₹679-766
• Results date: July-August 2026 (indicative)

It also notes that quarterly financials for the current cycle were “not yet fully available” on certain data partners and advises tracking Screener.in and NSE/BSE filings directly.

Quick facts table

Company contact details cited in the data

The provided text includes the company’s address and contact points:

• Address: 5th Floor, D Block, iLabs Centre, Plot 18, Software Units Layout, Survey No. 64, Madhapur, Shaikpet
• City/State/Pin: Hyderabad, Telangana 500081
• Tel: 040-42408039
• Email: cs@nephroplus.com
• Website: https://www.nephroplus.com

Market impact: what the numbers change right now

The key market impact from the June 2026 quarter snapshot is the reported swing to a profit of ₹1.61 crore, along with a reported 68.44% rise in sales to ₹29.19 crore. For investors, this combination often matters because sales growth without profitability improvement can be harder to sustain, while a profit swing can change how near-term execution is perceived.

At the same time, the market snapshot lists P/E as “not meaningful,” which usually signals that trailing earnings may not be a stable base for valuation comparisons in common screeners. With the board meeting scheduled for 11 August 2026, investors will likely focus on the officially released income statement, cash flow items, and any management commentary included in filings.

Analysis: why this update matters

Two threads stand out in the data: the short-term quarter snapshot and the larger FY26 scale metrics. The quarter snapshot points to a smaller reported profit base (₹1.61 crore) and relatively modest sales (₹29.19 crore), while FY26 numbers show revenue close to ₹1,000 crore and adjusted PAT of ₹128.3 crore.

Because the dataset mixes multiple sources and periods, the immediate analytical takeaway is procedural: the 11 August 2026 board meeting outcome and the filed results will be the key reference point. Investors can then reconcile the June quarter numbers with the company’s annual operating context, including the reported adjusted EBITDA margin (23.8%), cash balance (₹500 crore), and one-time items such as the ₹10 crore ECL provision noted for Q4.

Conclusion

Nephrocare Health Services heads into its 11 August 2026 board meeting with market attention on the quarter ended June 2026, where the provided data reports net profit of ₹1.61 crore on sales of ₹29.19 crore. The next concrete step is the company’s unaudited standalone and consolidated result filing for the quarter ended 30 June 2026, which should provide the definitive set of numbers and disclosures.